Lausanne, Switzerland, July 3, 2023 – AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at ...
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...
The purpose of this undergraduate minor is to leverage Drexel’s unique strengths and leadership in this area to advance the education of the next generation of leaders in immune engineering. Students ...
- Company to further expand its DECODE™ discovery platform, accelerate multiple oncology clinical programs, and advance discovery programs in oncology, autoimmune disorders, infectious disease, and ...
The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer program Target ALS Foundation grant supports collaboration between AC Immune and ...
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that, following advancement of key startup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results